S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

IntelGenx Technologies Stock Forecast, Price & News

+0.01 (+1.75 %)
(As of 10/6/2021)
Today's Range
50-Day Range
52-Week Range
Volume11,848 shs
Average Volume56,279 shs
Market CapitalizationC$87.32 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IGX News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
C$1.75 million
Cash Flow
C$0.08 per share
Book Value
C$0.05 per share





Market Cap
C$87.32 million
Next Earnings Date
11/10/2021 (Estimated)
Not Optionable


Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

IntelGenx Technologies (CVE:IGX) Frequently Asked Questions

What stocks does MarketBeat like better than IntelGenx Technologies?

Wall Street analysts have given IntelGenx Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IntelGenx Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IntelGenx Technologies' next earnings date?

IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for IntelGenx Technologies

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (CVE:IGX) released its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter.
View IntelGenx Technologies' earnings history

How has IntelGenx Technologies' stock price been impacted by COVID-19 (Coronavirus)?

IntelGenx Technologies' stock was trading at C$0.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IGX stock has increased by 7.4% and is now trading at C$0.58.
View which stocks have been most impacted by COVID-19

Who are IntelGenx Technologies' key executives?

IntelGenx Technologies' management team includes the following people:
  • Dr. Horst G. Zerbe, Chairman, CEO & Chairman of Scientific Advisory Board (Age 74, Pay $240.75k)
  • Mr. André Godin C.A., CPA, CPA, CA, Pres & CFO (Age 57, Pay $223.6k)
  • Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp (Age 44, Pay $140.13k)
  • Dr. Dana Matzen, VP of Bus. & Corp. Devel. of IntelGenx Corp (Age 43, Pay $171.43k)
  • Stephen Kilmer, Investor Relations Officer
  • Dr. Rodolphe Obeid Ph.D., VP of Operations - IntelGenx Corp (Age 41)
  • Mr. Tommy Kenny J.D., L.L.B., M.Sc., VP of Intellectual Property & Legal Affairs and Gen. Counsel of IntelGenx Corp (Age 34)
  • Ms. Ingrid Zerbe, Corp. Sec. (Age 67)

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include IntelGenx Technologies (IGXT), Aurora Cannabis (ACB), New Age Brands (NF), Capstone Mining (CS), Hanesbrands (HBI), Tilray (TLRY), ACADIA Pharmaceuticals (ACAD), AusCann Group (AC8), Cameco (CCJ) and Baylin Technologies (BYL).

What is IntelGenx Technologies' stock symbol?

IntelGenx Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."

How do I buy shares of IntelGenx Technologies?

Shares of IGX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is IntelGenx Technologies' stock price today?

One share of IGX stock can currently be purchased for approximately C$0.58.

How much money does IntelGenx Technologies make?

IntelGenx Technologies has a market capitalization of C$87.32 million and generates C$1.75 million in revenue each year.

How many employees does IntelGenx Technologies have?

IntelGenx Technologies employs 48 workers across the globe.

What is IntelGenx Technologies' official website?

The official website for IntelGenx Technologies is www.intelgenx.com.

How can I contact IntelGenx Technologies?

The company can be reached via phone at 514-331-7440.

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.